MedTrace Logo

Brazilian Reality of Urinary Bladder Cancers - BRA-BLADDER

NCT05945108 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2025-04-11

No results posted yet for this study

Summary

A national, multicenter, non-randomized, retrospective, observational study (Real-World Evidence-RWE) aimed at analyzing clinical presentation profiles and demographic characteristics of patients with early urothelial bladder cancer (high-risk non-muscle invasive and localized muscle-invasive) treated with standard therapies in national cancer treatment reference centers within the last 6 years (between 2017 and 2022).

Conditions

Sponsors & Collaborators

  • Hospital Israelita Albert Einstein

    collaborator OTHER

  • AstraZeneca

    lead INDUSTRY

Principal Investigators

  • Fernando Maluf, MD · Hospital Israelita Albert Einstein

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-10
Primary Completion
2024-04-18
Completion
2024-04-18

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05945108 on ClinicalTrials.gov